Pfizer PFE

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines

    Related Topics:

    1. Exclusive: Pfizer is mystery bidder for rare disease drugmaker Sobi - sources

      Headlines

      Thu, 30 Apr 2015

      NEW YORK/LONDON (Reuters) - Pfizer Inc is the mystery bidder for Swedish Orphan Biovitrum AB , the rare disease specialist which disclosed this week that a potential buyer had made a preliminary offer, people with knowledge of the situation said.

    2. Incyte Reports Solid 1Q as Attractive Pipeline Continues to Progress

      Commentary

      Thu, 30 Apr 2015

      potential catalyst for the company, we believe it will face a challenging environment given the disappointing launch of Pfizer 's Xeljanz. In addition, its broad Phase II program for its IDO1 inhibitor INCB24360 continues to advance in combination

    3. Bayer Posts Steady 1Q as Health Care Strength Offsets Material Science Weakness

      Commentary

      Thu, 30 Apr 2015

      pipeline. Several of Bayer’s cancer drugs (ODM-201, BAY 86-9766, copanlisib) will enter crowded markets. Also, cardiometabolic drug finerenone holds a similar mechanism of action as Pfizer ’s failed eplerenone.

    4. Icon Reports Solid 1Q, Continued Margin Improvements; Maintaining Fair Value Estimate

      Commentary

      Wed, 29 Apr 2015

      appears to be concerns that the firm's largest customer ( Pfizer ) has added a third preferred contract research organization ..... monitor any changing dynamics in the firm's bookings with Pfizer . Management updated its 2015 guidance to $3.60-3

    5. The Case Against the S&P 500

      Headlines

      Tue, 28 Apr 2015

      the first quarter is because nearly 4% of the index is in Apple ( AAPL ), which advanced by about 13%. Drugmaker Pfizer ( PFE ) is the index’s tenth holding and also had positive performance in the quarter. Over the past 12 months, Apple

    6. UPDATE 1- Pfizer cuts full-year forecast on stronger dollar

      Headlines

      Tue, 28 Apr 2015

      April 28 (Reuters) - U.S. drugmaker Pfizer Inc cut its full-year revenue and profit forecast, blaming a stronger dollar.

    7. Hospira Posts Impressive First-Quarter Results as Pfizer Buyout Nears

      Commentary

      Tue, 28 Apr 2015

      Hospira’s near-term outlook, we’re leaving our $90 fair value estimate and narrow moat rating unchanged prior to Pfizer ’s buyout later this year. Greater market expansion of the company’s biosimilars portfolio, manufacturing at the

    8. Pfizer quarterly revenue falls on stronger dollar

      Headlines

      Tue, 28 Apr 2015

      April 28 (Reuters) - Pfizer Inc reported a 4 percent fall in quarterly revenue, hurt by a stronger dollar.

    9. New Drug Launches and Prevnar Label Expansion in Pfizer ’s 1Q Help Offset Generic Competition

      Commentary

      Tue, 28 Apr 2015

      Weighed down by generic competition, Pfizer reported first-quarter results that ..... we wouldn’t be surprised if Pfizer made a bid for a large-cap drug ..... Novartis and Eli Lilly, we believe Pfizer ’s first-mover advantage will

    10. From Barron’s, April 27, 2015 (Part 2)

      Commentary

      Sat, 25 Apr 2015

      from NAV 25% ; 29% family owned; pg 20]; small-cap aerospace supplier Esterline Technologies [ ESL ; pg 29]; Pfizer [ PFE ; future split? Pg39]; Nippon Steel & Sumiromo Metal [5401.ja/ NISTY ; pg 39]. QCOM story http://online

    « Prev12345Next »
    Content Partners